

# Bell Palsy: Rapid Evidence Review

Sarah N. Dalrymple, MD; Jessica H. Row, MD; and John Gazewood, MD, MSPH

University of Virginia, Charlottesville, Virginia

**Bell palsy should be suspected in patients with acute onset of unilateral facial weakness or paralysis involving the forehead in the absence of other neurologic abnormalities. The overall prognosis is good. More than two-thirds of patients with typical Bell palsy have a complete spontaneous recovery. For children and pregnant women, the rate of complete recovery is up to 90%. Bell palsy is idiopathic. Laboratory testing and imaging are not required for diagnosis. When other causes of facial weakness are being considered, laboratory testing may identify a treatable cause. An oral corticosteroid regimen (prednisone, 50 to 60 mg per day for five days followed by a five-day taper) is the first-line treatment for Bell palsy. Combination therapy with an oral corticosteroid and antiviral may reduce rates of synkinesis (misdirected regrowth of facial nerve fibers manifesting as involuntary co-contraction of certain facial muscles). Recommended antivirals include valacyclovir (1 g three times per day for seven days) or acyclovir (400 mg five times per day for 10 days). Treatment with antivirals alone is ineffective and not recommended. Physical therapy may be beneficial in patients with more severe paralysis. (*Am Fam Physician*. 2023;107(4):415-420. Copyright © 2023 American Academy of Family Physicians.)**

**Bell palsy** is acute facial paralysis or weakness caused by peripheral cranial nerve VII (facial) dysfunction of unknown etiology. This article provides a brief overview of patient-oriented evidence for the primary care of patients with Bell palsy.

## Epidemiology

- The estimated incidence of Bell palsy is 20 to 30 cases per 100,000 people per year.<sup>1-4</sup>
- All ages can be affected, with the highest incidence in people 15 to 45 years of age.<sup>1-4</sup>
- Women and men are equally affected.<sup>1,2</sup>
- An equal number of left-sided and right-sided cases are reported.<sup>3,5</sup>
- Bell palsy is associated with nerve edema and mechanical compression of cranial nerve VII.<sup>6</sup> The anatomy of this nerve is illustrated in *Figure 1*.<sup>7</sup>

**CME** This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 348.

**Author disclosure:** No relevant financial relationships.

**Patient information:** A handout on this topic is available with the online version of this article.

- Based on epidemiologic studies, risk factors include diabetes mellitus, hypertension, immunosuppression, influenza A and other upper respiratory illnesses, and pregnancy.<sup>1,2,3,5,8,9</sup>

## Diagnosis

- Bell palsy should be suspected in patients with acute onset of unilateral facial weakness or paralysis involving the forehead in the absence of other neurologic abnormalities.<sup>4</sup>
- Alternative diagnoses should be considered in patients with bilateral involvement, sparing of the forehead, abnormal extraocular movements, hearing loss, tinnitus, or vertigo. These findings indicate an upper motor neuron lesion or a lesion involving more than just cranial nerve VII<sup>10</sup> (*Figure 2*).
- Other diagnoses should be considered in patients with gradual onset of symptoms, prolonged course (more than three months without improvement), limb or bulbar weakness, systemic or localized facial skin cancer, signs of infection, or risk of infection.<sup>11</sup>
- Additional evaluation should be considered in patients with ipsilateral recurrent Bell palsy because this could suggest an underlying tumor.<sup>12</sup>

**SORT: KEY RECOMMENDATIONS FOR PRACTICE**

Clinical recommendation	Evidence rating	Comments
Patients with Bell palsy should be prescribed oral corticosteroids. <sup>3,17,18</sup>	<b>A</b>	Meta-analysis with high degree of certainty
Combination therapy with oral corticosteroids and antivirals should be considered in patients with Bell palsy to reduce rates of synkinesis. <sup>5,17,18,22</sup>	<b>B</b>	Meta-analysis with moderate degree of certainty
Patients with Bell palsy should not be treated with antivirals alone. <sup>5,17,22</sup>	<b>A</b>	Meta-analysis with high degree of certainty
Physical therapy should be offered to patients with severe paralysis (House-Brackmann grade V or VI) or persistent paralysis (more than three months). <sup>28,29</sup>	<b>B</b>	Cochrane review of lower-quality studies; one high-quality randomized trial

**A** = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

• The differential diagnosis of Bell palsy includes structural lesions, infection, autoimmune conditions, stroke, and multiple sclerosis (*Table 1*).<sup>7</sup>

**SIGNS AND SYMPTOMS**

• Bell palsy presents as mouth droop, flattening of the nasolabial fold, inability to close the eye, and smoothing of the brow on one side of the face.<sup>13</sup>

• Symptoms of Bell palsy are rarely bilateral.<sup>14</sup>


• Symptoms typically develop acutely (over one to three days), peak within the first week, and gradually resolve over weeks to months.

• Patients with Bell palsy experience a spectrum of symptom severity. The Sunnybrook scale (<https://sunnybrook.ca/uploads/FacialGradingSystem.pdf>) and House-Brackmann scale are commonly used to classify symptom severity.

- House-Brackmann scale<sup>15</sup>:
  - Grade I, normal severity: normal facial function in all areas.
  - Grade II, slight severity: slight weakness on close inspection, slight synkinesis, complete eyelid closure with minimal effort.
  - Grade III, moderate severity: Obvious but not disfiguring facial asymmetry, synkinesis is noticeable but not severe, may have hemifacial spasm or contracture, complete eyelid closure with effort, mouth is slightly weak with maximal effort.
  - Grade IV, moderately severe: Disfiguring facial asymmetry or obvious facial weakness, forehead cannot move, incomplete eyelid closure, mouth is asymmetrical with maximal effort.
  - Grade V, total paralysis: no facial movement.

• Physical examination maneuvers to demonstrate the degree and extent of facial weakness include having patients raise their eyebrows, close their eyes, frown, show their teeth, and pucker their lips.

**FIGURE 1**



© Renee Cannon

**Anatomy of the facial nerve.**

Illustration by Renee Cannon

Reprinted with permission from Tiemstra JD, Khatkhate N. Bell's palsy: diagnosis and management. *Am Fam Physician.* 2007;76(7):999.

## BELL PALSY

- Patients who can close their eyes tightly and wrinkle their forehead on the affected side should be evaluated for a central lesion.

### DIAGNOSTIC TESTING

- Laboratory tests and radiography are not needed to diagnose Bell palsy.
- Laboratory tests can identify systemic causes of peripheral facial palsy such as diabetes and Lyme disease.
- Magnetic resonance imaging of the head or orbits/face/neck, with and without intravenous contrast, is recommended in patients with recurrent Bell palsy.<sup>16</sup>

### Treatment

- *Figure 3* presents a suggested approach to the treatment of Bell palsy.

### MEDICAL THERAPY

- Patients with Bell palsy should be treated with oral corticosteroids, which have been shown to improve rates of full recovery (number needed to treat = 10) and reduce rates of synkinesis in adults.<sup>3,17,18</sup> Typical prednisone doses reported in trials range from 50 to 60 mg per day for five days followed by a five-day taper.<sup>3,17</sup>
- A meta-analysis compared rates of unsatisfactory recovery for a cumulative corticosteroid dose of less than 450 mg vs. 450 mg or more. Unsatisfactory recovery was more likely with the lower dose range compared with the higher range (30% vs. 14%).<sup>17</sup>
- Patients with Bell palsy should be offered combination therapy with oral corticosteroids and antivirals.<sup>5,19-21</sup> Combination therapy consistently leads to lower rates of synkinesis (number needed to treat = 12).<sup>5,17,18,22</sup>
- The effectiveness of combination therapy for improving rates of complete recovery in patients with Bell palsy is unclear.

- Two meta-analyses of higher-quality trials showed that combination therapy does not increase rates of complete recovery.<sup>5,22</sup>

- Meta-analyses and a network meta-analysis of heterogeneous low-quality trials showed that combination therapy

may reduce rates of incomplete recovery without an increase in adverse events.<sup>5,18,22</sup>


- Regimens of antiviral therapy reported in trials included valacyclovir, 1 g three times per day for seven days, and acyclovir, 400 mg five times per day for 10 days. Treatment outcomes were similar regardless of disease severity.<sup>5,22</sup>

- Oral antivirals are well tolerated.<sup>5</sup> There are no compelling effectiveness data to recommend one antiviral over another.<sup>23</sup>

- Although there is limited evidence showing that corticosteroids are beneficial in pregnant patients with Bell palsy, consensus practice is to treat these patients similarly to non-pregnant adults, with corticosteroids early in the disease course.<sup>9,24</sup>

- A study that randomized 187 children to treatment with prednisolone or placebo within three days of symptom onset

FIGURE 2



Patients with (A) a cranial nerve VII (facial) lesion (Bell palsy) and (B) supranuclear lesion with forehead sparing.

Illustration by Renee Cannon

Reprinted with permission from Tiemstra JD, Khatkhate N. Bell's palsy: diagnosis and management. *Am Fam Physician*. 2007;76(7):998.

TABLE 1

**Differential Diagnosis of Facial Weakness**

Diagnosis	Cause	Distinguishing factors
<b>Peripheral</b>		
Lyme disease	Spirochete <i>Borrelia burgdorferi</i>	History of tick exposure, rash, or arthralgias; residing in or travel to endemic regions; bilateral facial weakness
Otitis media	Bacterial pathogens	Gradual onset; ear pain, fever, conductive hearing loss
Viral infections	COVID-19, cytomegalovirus, Epstein-Barr virus, herpes simplex, HIV, influenza A, mumps, rubella, other viruses	Coryza; symptoms of specific viral infections
Ramsay Hunt syndrome	Herpes zoster virus	Pronounced prodromal pain; vesicular eruption in ear canal or pharynx
Sarcoidosis, myasthenia gravis, or Guillain-Barré syndrome	Autoimmune response	More often bilateral
Tumor	Cholesteatoma, parotid gland tumor	Gradual onset
Melkersson-Rosenthal syndrome	Genetic condition	Onset in childhood or early adolescence; associated facial swelling, fissured tongue
Iatrogenic	Botulinum toxin injection	Weakness at injection site
<b>Central (forehead spared)</b>		
Multiple sclerosis	Demyelination	Other neurologic symptoms
Stroke	Ischemia, hemorrhage	Extremities on affected side often involved; other neurologic symptoms (e.g., aphasia, unilateral neglect, sensory loss)
Tumor	Metastases, primary brain tumor	Gradual onset; mental status changes, history of cancer

Adapted with permission from Tiemstra JD, Khatkhate N. Bell's palsy: diagnosis and management. *Am Fam Physician*. 2007;76(7):1000.

found no difference in rates of complete recovery of facial function at one, three, and six months.<sup>6,25</sup>

• Patients with Bell palsy should not be treated with antivirals alone. There is strong evidence that antivirals alone have no effect on recovery.<sup>5,17,22</sup>

complete spontaneous recovery within three weeks, and this rate increases within eight weeks.<sup>29-39</sup>

• Up to 90% of children younger than 14 years and pregnant patients will experience complete spontaneous recovery.<sup>6,9</sup>

**SURGICAL TREATMENT**

• There is insufficient evidence to determine whether surgical decompression of cranial nerve VII improves outcomes in patients with severe Bell palsy.<sup>26,27</sup>

**EYE CARE**

• Patients with Bell palsy who are not able to close an eye should be educated about eye protection measures (e.g., administration of liquid tears or lubricating gel, eyelid taping at night). Signs or symptoms of keratitis warrant referral to an eye specialist.<sup>19-21</sup>

**PHYSICAL THERAPY**

• Facial physical therapy should be offered to patients with severe or complete paralysis (House-Brackmann grade V or VI) or prolonged paralysis (more than three months), based on a Cochrane review of lower-quality studies and on one high-quality randomized trial.<sup>28,29</sup> It is unclear whether electrostimulation is effective, and there is evidence that it may worsen outcomes.<sup>28,30,31</sup>

• There is no high-quality evidence showing that treatment with low-level or high-level laser therapy, hyperbaric oxygen, intratympanic steroid injections, or stellate ganglion blocks is more effective than standard medical therapy.<sup>32-35</sup>

**COMPLEMENTARY AND ALTERNATIVE MEDICINE**


• There is insufficient high-quality evidence to recommend acupuncture for the treatment of early Bell palsy or its sequelae.<sup>19,36-38</sup>

**Prognosis**

• Between 66% and 85% of patients who have Bell palsy will experience



FIGURE 3



**Approach to the treatment of patients with Bell palsy.**

- Patients with bilateral disease or more severe peak symptoms (determined by the Sunnybrook or House-Brackmann scale) are less likely to experience full recovery.<sup>9</sup>
- The recurrence rate of Bell palsy has been reported as 6.5%, with a mean interval of 10 years. Of patients with recurrence, 66% experience complete recovery.<sup>12</sup>
- Synkinesis is a result of misdirected nerve regrowth and manifests as unintended ipsilateral co-contractions of muscles innervated by cranial nerve VII (e.g., contraction of the ipsilateral orbicularis oculi muscle [blinking] when smiling or when tearing with salivation [crocodile tears]). Synkinesis affects 26% of patients one year after onset of Bell palsy.<sup>3</sup>
- Long-term sequelae of Bell palsy, especially the impairment of smiling, may lead to severe anxiety, depression, and other psychological problems.<sup>40</sup>
- Neurology referral should be considered in patients with prolonged, bilateral, or recurrent symptoms.

This article updates previous articles on this topic by Tiemstra and Khatkhate,<sup>7</sup> and Albers and Tamang.<sup>41</sup>

**Data Sources:** PubMed was searched using the key terms Bell’s palsy, Bell palsy, facial nerve palsy for human studies, systematic reviews, and meta-analyses published after January 1, 2012. Reference lists from key articles were reviewed for additional sources. Essential Evidence Plus was also reviewed. Search dates: March and April 2022, January 12, 2023.

**The Authors**

**SARAH N. DALRYMPLE, MD**, is an assistant professor in the Department of Family Medicine at the University of Virginia, Charlottesville.

**JESSICA H. ROW, MD**, is a resident physician in the Department of Family Medicine at the University of Virginia.

**JOHN GAZEWOOD, MD, MSPH**, is residency program director, vice chair, and an associate professor in the Department of Family Medicine at the University of Virginia.

Address correspondence to Sarah N. Dalrymple, MD, University of Virginia, 1221 Lee St., Box 800729, Charlottesville, VA 22908 (email: sdalrymple@virginia.edu). Reprints are not available from the authors.

**References**

1. Greco A, Gallo A, Fusconi M, et al. Bell’s palsy and autoimmunity. *Autoimmun Rev*. 2012;12(2):323-328.
2. Skuladottir AT, Bjornsdottir G, Thorleifsson G, et al. A meta-analysis uncovers the first sequence variant conferring risk of Bell’s palsy. *Sci Rep*. 2021;11(1):4188.
3. Madhok VB, Gagyor I, Daly F, et al. Corticosteroids for Bell’s palsy (idiopathic facial paralysis). *Cochrane Database Syst Rev*. 2016;(7):CD001942.
4. Gilden DH. Clinical practice. Bell’s Palsy. *N Engl J Med*. 2004;351(13):1323-1331.
5. Gagyor I, Madhok VB, Daly F, et al. Antiviral treatment for Bell’s palsy (idiopathic facial paralysis). *Cochrane Database Syst Rev*. 2019;(9):CD001869.
6. Pitaro J, Waissbluth S, Daniel SJ. Do children with Bell’s palsy benefit from steroid treatment? A systematic review. *Int J Pediatr Otorhinolaryngol*. 2012;76(7):921-926.
7. Tiemstra JD, Khatkhate N. Bell’s palsy: diagnosis and management. *Am Fam Physician*. 2007;76(7):997-1002.
8. Adour K, Wingerd J, Doty HE. Prevalence of concurrent diabetes mellitus and idiopathic facial paralysis (Bell’s palsy). *Diabetes*. 1975;24(5):449-451.
9. Cohen Y, Lavie O, Granovsky-Grisaru S, et al. Bell palsy complicating pregnancy: a review. *Obstet Gynecol Surv*. 2000;55(3):184-188.
10. Dulak D, Naqvi IA. Neuroanatomy, cranial nerve 7 (facial). StatPearls Updated July 25, 2022. Accessed January 12, 2023. <http://www.ncbi.nlm.nih.gov/books/NBK526119/>
11. Reich SG. Bell’s palsy. *Continuum (Minneapolis)*. 2017;23(2, Selected Topics in Outpatient Neurology):447-466.
12. Dong SH, Jung AR, Jung J, et al. Recurrent Bell’s palsy. *Clin Otolaryngol*. 2019;44(3):305-312.
13. Warner MJ, Hutchison J, Varacallo M. Bell palsy. StatPearls. Updated September 4, 2022. Accessed January 11, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK482290/>
14. Pothiwala S, Lateef F. Bilateral facial nerve palsy: a diagnostic dilemma. *Case Rep Emerg Med*. 2012;2012:458371.
15. House JW, Brackmann DE. Facial nerve grading system. *Otolaryngol Head Neck Surg*. 1985;93(2):146-147.
16. Policeni B, Corey AS, Burns J, et al.; Expert Panel on Neurologic Imaging. ACR Appropriateness Criteria® cranial neuropathy. *J Am Coll Radiol*. 2017;14(11S):S406-S420.
17. de Almeida JR, Al Khabori M, Guyatt GH, et al. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. *JAMA*. 2009;302(9):985-993.
18. Jalali MM, Soleimani R, Soltanipour S, et al. Pharmacological treatments of Bell’s palsy in adults: a systematic review and network meta-analysis. *Laryngoscope*. 2021;131(7):1615-1625.
19. Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell’s palsy. *Otolaryngol Head Neck Surg*. 2013;149(3 suppl):S1-S27.

## BELL PALSY

20. de Almeida JR, Guyatt GH, Sud S, et al.; Bell Palsy Working Group, Canadian Society of Otolaryngology - Head and Neck Surgery and Canadian Neurological Sciences Federation. Management of Bell palsy: clinical practice guideline. *CMAJ*. 2014;186(12):917-922.
21. Fieux M, Franco-Vidal V, Devic P, et al. French Society of ENT (SFORL) guidelines. Management of acute Bell's palsy. *Eur Ann Otorhinolaryngol Head Neck Dis*. 2020;137(6):483-488.
22. Turgeon RD, Wilby KJ, Ensom MHH. Antiviral treatment of Bell's palsy based on baseline severity: a systematic review and meta-analysis. *Am J Med*. 2015;128(6):617-628.
23. Cao J, Zhang X, Wang Z. Effectiveness comparisons of antiviral treatments for Bell palsy: a systematic review and network meta-analysis [published correction appears in *J Neurol*. 2022;269(3):1368]. *J Neurol*. 2022;269(3):1353-1367.
24. Evangelista V, Gooding MS, Pereira L. Bell's palsy in pregnancy. *Obstet Gynecol Surv*. 2019;74(11):674-678.
25. Babl FE, Herd D, Borland M, et al.; Paediatric Research in Emergency Departments International Collaborative (PREDICT). Efficacy of prednisolone for bell palsy in children: a randomized, double-blind, placebo-controlled, multicenter trial [published online August 25, 2022]. *Neurology*. Accessed September 30, 2022.
26. Menchetti I, McAllister K, Walker D, et al. Surgical interventions for the early management of Bell's palsy. *Cochrane Database Syst Rev*. 2021;(1):CD007468.
27. Casazza GC, Schwartz SR, Gurgel RK. Systematic review of facial nerve outcomes after middle fossa decompression and transmastoid decompression for Bell's palsy with complete facial paralysis. *Otol Neurotol*. 2018;39(10):1311-1318.
28. Teixeira LJ, Valbuza JS, Prado GF. Physical therapy for Bell's palsy (idiopathic facial paralysis). *Cochrane Database Syst Rev*. 2011;(12):CD006283.
29. Nicastrì M, Mancini P, De Seta D, et al. Efficacy of early physical therapy in severe Bell's palsy: a randomized controlled trial. *Neurorehabil Neural Repair*. 2013;27(6):542-551.
30. Kim J, Choi JY. The effect of subthreshold continuous electrical stimulation on the facial function of patients with Bell's palsy. *Acta Otolaryngol*. 2016;136(1):100-105.
31. Marotta N, Demeco A, Inzitari MT, et al. Neuromuscular electrical stimulation and shortwave diathermy in unrecovered Bell palsy: a randomized controlled study. *Medicine (Baltimore)*. 2020;99(8):e19152.
32. Javaherian M, Attarbashi Moghaddam B, Bashardoust Tajali S, et al. Efficacy of low-level laser therapy on management of Bell's palsy: a systematic review. *Lasers Med Sci*. 2020;35(6):1245-1252.
33. Alayat MSM, Elsodany AM, El Fiky AAR. Efficacy of high and low level laser therapy in the treatment of Bell's palsy: a randomized double blind placebo-controlled trial. *Lasers Med Sci*. 2014;29(1):335-342.
34. Holland NJ, Bernstein JM, Hamilton JW. Hyperbaric oxygen therapy for Bell's palsy. *Cochrane Database Syst Rev*. 2012;(2):CD007288.
35. Chung JH, Park CW, Lee SH, et al. Intratympanic steroid injection for Bell's palsy: preliminary randomized controlled study. *Otol Neurotol*. 2014;35(9):1673-1678.
36. Chen N, Zhou M, He L, et al. Acupuncture for Bell's palsy. *Cochrane Database Syst Rev*. 2010;(8):CD002914.
37. Tong FM, Chow SK, Chan PYB, et al. A prospective randomised controlled study on efficacies of acupuncture and steroid in treatment of idiopathic peripheral facial paralysis. *Acupunct Med*. 2009;27(4):169-173.
38. Zhang R, Wu T, Wang R, et al. Compare the efficacy of acupuncture with drugs in the treatment of Bell's palsy: a systematic review and meta-analysis of RCTs. *Medicine (Baltimore)*. 2019;98(19):e15566.
39. Peitersen E. Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. *Acta Otolaryngol Suppl*. 2002;(549):4-30.
40. Fu L, Bundy C, Sadiq SA. Psychological distress in people with disfigurement from facial palsy. *Eye (Lond)*. 2011;25(10):1322-1326.
41. Albers JR, Tamang S. Common questions about Bell palsy. *Am Fam Physician*. 2014;89(3):209-212.